Can you provide the last earnings date for AYTU BIOPHARMA INC?
AYTU BIOPHARMA INC (AYTU) last reported earnings on 2/3/2026.
AYTU BIOPHARMA INC (AYTU) Earnings History & Surprises
NASDAQ:AYTU • US0547548588
Current stock price
2.56 USD
-0.03 (-1.16%)
Last:
AYTU Earnings overview
Past quarterly earnings results for AYTU BIOPHARMA INC (AYTU), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 12, 2026
- Period
- Q3 / 2026
- EPS Estimate
- -$0.58
- Revenue Estimate
- 13.552M
Last Reported
Most Recent- Release Date
- Feb 3, 2026
- Period
- Q2 / 2026
- EPS Reported
- -$1.05
- EPS Surprise
- -71.57%
- Revenue Surprise
- 22.12%
Beat Rate
Last 8 Quarters 69%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | -1.05 | -0.61 | -71.57% | -303.85% | 15.165M | 12.418M | 22.12% | -6.51% |
| Q1 2026 | 0.21 | -0.23 | 189.51% | -52.27% | 13.888M | 12.645M | 9.83% | -14.38% |
| Q4 2025 | -2.92 | -0.04 | -7,706.78% | -256.10% | 15.135M | 18.28M | -17.20% | -15.80% |
| Q3 2025 | 0.21 | -0.17 | 221.11% | 140.38% | 18.452M | 14.014M | 31.67% | 2.55% |
| Q2 2025 | -0.26 | -0.29 | 8.96% | -550.00% | 16.221M | 15.865M | 2.24% | -29.27% |
| Q1 2025 | 0.44 | -0.35 | 226.87% | 129.73% | 16.221M | 14.043M | 15.51% | -26.60% |
| Q4 2024 | -0.82 | -0.46 | -78.65% | -38.98% | 17.976M | 18.667M | -3.70% | -41.51% |
| Q3 2024 | -0.52 | -0.65 | 20.34% | 73.06% | 17.993M | 17.693M | 1.70% | -20.85% |
| Q2 2024 | -0.04 | -0.26 | 84.31% | 96.95% | 22.934M | 22.18M | 3.40% | -12.73% |
| Q1 2024 | -1.48 | -0.04 | -3,527.45% | -23.33% | 22.099M | 28.281M | -21.86% | -20.10% |
| Q4 2023 | -0.59 | -0.97 | 39.11% | 93.98% | 30.732M | 28.248M | 8.79% | 11.96% |
| Q3 2023 | -1.93 | -0.64 | -200.34% | 94.61% | 22.733M | 28.56M | -20.40% | -6.06% |
| Q2 2023 | -1.31 | -1.63 | 19.73% | 85.11% | 26.28M | 26.928M | -2.41% | 13.62% |
| Q1 2023 | -1.20 | -3.67 | 67.32% | 94.50% | 27.66M | 24.786M | 11.60% | 26.30% |
| Q4 2022 | -9.80 | -7.55 | -29.84% | 34.67% | 27.45M | 26.01M | 5.54% | 16.91% |
| Q3 2022 | -35.80 | -8.36 | -328.02% | -26.95% | 24.2M | 25.296M | -4.33% | 79.53% |
| Q2 2022 | -8.80 | -11.83 | 25.63% | 37.14% | 23.13M | 27.744M | -16.63% | 52.67% |
| Q1 2022 | -21.80 | -10.00 | -118.09% | -172.50% | 21.9M | 22.542M | -2.85% | 61.98% |
| Q4 2021 | -15.00 | -10.00 | -50.06% | -275.00% | 23.48M | 21.318M | 10.14% | 58.01% |
| Q3 2021 | -28.20 | -6.43 | -338.84% | 6.00% | 13.48M | 14.346M | -6.04% | 65.20% |
| Q2 2021 | -14.00 | -8.98 | -55.97% | -600.00% | 15.15M | 12.495M | 21.25% | 376.42% |
| Q1 2021 | -8.00 | -11.22 | 28.70% | 87.50% | 13.52M | 13.597M | -0.57% | 838.89% |
| Q4 2020 | -4.00 | -7.14 | 43.98% | - | 14.86M | 11.465M | 29.61% | - |
| Q3 2020 | -30.00 | -44.88 | 33.16% | - | 8.16M | 6.533M | 24.90% | - |
| Q2 2020 | -2.00 | -49.98 | 96.00% | - | 3.18M | 2.792M | 13.90% | - |
| Q1 2020 | -64.00 | -56.10 | -14.08% | - | 1.44M | 2.055M | -29.93% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-1,841.93%
Max EPS beat (4)
221.11%
Min EPS beat (4)
-7,706.78%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
11.60%
Max Revenue beat (4)
31.67%
Min Revenue beat (4)
-17.20%
Analysis
In the last 4 quarters, AYTU has beaten EPS estimates in 2 out of 4 releases
AYTU has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, AYTU reported -1841.9% below the EPS estimates on average.
In the last 4 quarters, AYTU has beaten the revenue estimates by 11.6% on average.
Related analysis
AYTU BIOPHARMA INC / AYTU Earnings FAQ
Can you provide information on whether AYTU BIOPHARMA INC beat earnings estimates in the last quarter?
AYTU BIOPHARMA INC (AYTU) missed EPS estimates and beat revenue estimates in the most recent quarter.
How often does AYTU BIOPHARMA INC (AYTU) beat earnings estimates?
In the last 4 quarters, AYTU BIOPHARMA INC (AYTU) has beaten EPS estimates in 2 out of 4 releases.